These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15329034)

  • 21. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators.
    Clahsen PC; van de Velde CJ; Welvaart K; van Driel OJ; Sylvester RJ
    J Clin Oncol; 1995 Jan; 13(1):33-41. PubMed ID: 7799039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
    Bokemeyer C
    Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The advancement of high-dose chemotherapy and dose intensification schedules.
    Leonard RC
    Ann Oncol; 1997; 8 Suppl 3():S3-6. PubMed ID: 9341958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapy with autologous stem cell support for breast cancer].
    Tajima T; Tokuda Y; Okumura T; Kubota M; Mitomi T
    Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():255-8. PubMed ID: 7913601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of chemotherapy in metastatic breast cancer.
    Garber JE; Henderson IC
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of high-dose chemotherapy in solid tumours.
    Nieboer P; de Vries EG; Mulder NH; van der Graaf WT
    Cancer Treat Rev; 2005 May; 31(3):210-25. PubMed ID: 15944050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemotherapy in advanced breast cancer.
    Viens P; Maraninchi D
    Crit Rev Oncol Hematol; 2002 Feb; 41(2):141-9. PubMed ID: 11856590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer.
    Bearman SI; Shpall EJ; Jones RB; Cagnoni PJ; Ross M
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):60-7. PubMed ID: 8614848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.